Trough-Guided Voriconazole Dose Adjustment: Population PK Model Validated in 67 Patients
This single-center population pharmacokinetic (PopPK) analysis offers pharmacists a genotype-free, trough-based dose adjustment table for intravenous voriconazole, but the validation design limits how far its headline target attainment figure can be generalized.
📅 Journal publication: 2026(online Oct 19, 2026)·Last updated: Nov 6, 2026
voriconazoletriazole antifungalpopulation pharmacokineticsNONMEMtherapeutic drug monitoringMonte Carlo simulationinvasive fungal infectiondose optimizationC-reactive proteincreatinine clearanceomeprazoleretrospective studyPharmacokinetics / TDM
New model boosts voriconazole target concentration achievement by 44.74%.
Optimizing voriconazole dosing through pharmacokinetic modeling can enhance therapeutic outcomes and minimize toxicity. The model showed that adjusted dosing improved target plasma concentration achievement from 46.3% to 91.04% in a validation cohort. This study provides a dosing adjustment model for voriconazole that can significantly improve therapeutic drug monitoring outcomes, but the sample size was relatively small. Pharmacokinetic model-based dosing significantly increases achievement of target voriconazole plasma concentrations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Jiang L, Lin Z
Citation:Jiang L, Lin Z Population pharmacokinetic modeling of voriconazole based on real-world data for dosing regimen optimization. Frontiers in pharmacology. 2026;17:1979373. doi:10.3389/fphar.2026.1979373